Screener
MapLight Therapeutics, Inc. MPLT All Other Segments — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Employee-related research and development expenses | 15,993 | 7,050 |
| Chemistry, manufacturing and controls expenses | 6,417 | 3,956 |
| Preclinical program expenses | 5,522 | 6,081 |
| Other research and development expenses | 933 | 761 |
| Employee-related general and administrative expenses | 6,990 | 2,060 |
| Professional fees and other general and administrative expenses | 3,829 | 1,696 |
| Other segment items(1) | (3,835) | (1,203) |
| Net loss | $60,668 | $22,340 |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s all other segments — research and development expense?
- MapLight Therapeutics, Inc. (MPLT) reported all other segments — research and development expense of $933K in Q1 2026.
- How has MapLight Therapeutics, Inc.'s all other segments — research and development expense changed year-over-year?
- MapLight Therapeutics, Inc.'s all other segments — research and development expense increased by 22.6% year-over-year, from $761K to $933K.
- What does all other segments — research and development expense mean?
- This metric represents the aggregate costs incurred by the company's miscellaneous or non-core business segments for research and development activities. It captures expenditures related to the discovery, clinical testing, and development of therapeutic candidates that are not attributed to the primary reportable business units. Monitoring these expenses helps investors assess the company's total investment in its broader pipeline and the resource allocation strategy across secondary development programs.
Ask your AI about MapLight Therapeutics, Inc.'s all other segments — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude